Escitalopram: a review of its use in the management of major depressive disorder in adults.
Escitalopram (escitalopram oxalate; Cipralex, Lexapro), a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD), demonstrates a highly selective and potent, dose-dependent inhibition of the human serotonin transporter, inhibiting serotonin reuptake into presynaptic nerve terminals and thus increasing serotonergic activity in the CNS. With regard to primary endpoints (such as improved scores on the Montgomery-Asberg Depression Rating Scale [MADRS] and the Hamilton Depression Rating Scale [HAM-D]), escitalopram was generally more effective than placebo, at least as effective as citalopram, and generally at least as effective as other comparator drugs, including the SSRIs fluoxetine, paroxetine and sertraline, the serotonin-noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) venlafaxine extended release and duloxetine, and the aminoketone bupropion in adult patients with MDD in short-term, well designed trials. Moreover, it demonstrated a rapid onset of antidepressant action. Escitalopram was also found to be cost effective in several studies, dominating other SSRIs and venlafaxine extended release. Maintenance therapy is commonly required to prevent recurrence of depression. Long-term trials corroborated short-term results, with escitalopram demonstrating greater efficacy than placebo in relapse prevention. Additionally, escitalopram was at least as effective as citalopram, paroxetine and duloxetine in long-term comparative trials. Escitalopram has a predictable tolerability profile with generally mild to moderate and transient adverse events, and a low propensity for drug interactions. Sexual dysfunction with escitalopram treatment appeared to occur to a similar or lower extent to that with paroxetine (another SSRI), to a similar or greater extent to that with the SNRI duloxetine, and to a greater extent than that with the aminoketone bupropion. Thus, escitalopram is an effective and generally well tolerated treatment for moderate to severe MDD. Escitalopram, like other SSRIs, is an effective first-line option in the management of patients with MDD.
Garnock-Jones
Karly P
KP
Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
McCormack
Paul L
PL
D000328:Adult; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors
Epidemiol Rev. 2008;30:101-17
18753674
Pharmacogenet Genomics. 2009 Sep;19(9):666-74
19724244
CNS Drugs. 2003;17(5):343-62
12665392
Curr Med Res Opin. 2006 Jul;22(7):1331-41
16834832
Depress Anxiety. 2008;25(1):46-54
17149753
Prev Chronic Dis. 2008 Jan;5(1):A22
18082011
Psychopharmacology (Berl). 2011 Feb;213(2-3):639-46
20340011
Int Clin Psychopharmacol. 2008 Sep;23(5):276-86
18703937
J Clin Psychiatry. 2004 Jan;65(1):44-9
14744167
J Emerg Med. 2010 Jul;39(1):44-8
19081700
Pharmacoeconomics. 2003;21(16):1185-209
14594439
J Sex Med. 2007 Jul;4(4 Pt 1):917-29
17627739
Curr Med Res Opin. 2007 Feb;23(2):245-50
17288677
Curr Med Res Opin. 2007 Feb;23(2):401-16
17288694
Pharmacopsychiatry. 2007 Mar;40(2):53-7
17447173
Int Clin Psychopharmacol. 2009 May;24(3):119-25
19367152
J Clin Psychiatry. 2008 Mar;69(3):392-9
18348597
Psychopharmacol Bull. 2008;41(2):58-85
18668017
Curr Med Res Opin. 2007 Jul;23(7):1605-14
17559755
BMJ. 2005 Feb 19;330(7488):385
15718537
Am J Geriatr Pharmacother. 2006 Sep;4(3):201-9
17062320
Int Clin Psychopharmacol. 2002 May;17(3):95-102
11981349
J Neurochem. 2005 Jan;92(1):21-8
15606893
Curr Med Res Opin. 2007 Jun;23(6):1303-18
17559729
J Psychiatr Res. 2009 Jan;43(3):247-54
18511076
Ann Clin Psychiatry. 2006 Apr-Jun;18(2):83-9
16754413
Prim Care Companion J Clin Psychiatry. 2003 Aug;5(4):153-157
15213776
J Clin Psychiatry. 2002 Apr;63(4):331-6
12000207
Eur Neuropsychopharmacol. 2009 Apr;19(4):229-37
19185467
J Clin Psychopharmacol. 2006 Apr;26(2):172-7
16633147
Biol Psychiatry. 2001 Sep 1;50(5):345-50
11543737
Int Clin Psychopharmacol. 2006 May;21(3):159-69
16528138
Int J Psychiatry Clin Pract. 2009;13(1):59-69
24946123
Clin Drug Investig. 2007;27(7):481-92
17563128
Eur Neuropsychopharmacol. 2005 Mar;15(2):193-8
15695064
Int J Clin Pract. 2007 Apr;61(4):702-10
17394446
J Clin Pharmacol. 2005 Dec;45(12):1400-6
16291715
Am J Geriatr Psychiatry. 2007 Jul;15(7):581-93
17586783
J Clin Psychiatry. 2004 Sep;65(9):1190-6
15367045
Ann Pharmacother. 2007 Oct;41(10):1583-92
17848424
Br J Clin Pharmacol. 2003 Oct;56(4):415-21
12968986
Int J Clin Pract. 2005 Mar;59(3):268-75
15857321
CNS Drugs. 2006;20(9):763-90
16953656
J Biol Chem. 2006 Jan 27;281(4):2012-23
16272152
Neuropsychobiology. 2004;50(1):57-64
15179022
Psychopharmacology (Berl). 2007 Apr;191(2):333-9
17235610
J Med Assoc Thai. 2008 Jul;91(7):1117-28
18839855
Eur J Health Econ. 2005 Dec;6(4):317-21
16267659
Psychiatry Clin Neurosci. 2007 Oct;61(5):522-8
17875031
Neuropsychopharmacology. 2009 Jun;34(7):1819-28
19295509
Tidsskr Nor Laegeforen. 2005 Sep 22;125(18):2470-3
16186862
Paediatr Drugs. 2010 Jun;12(3):155-63
20481645
Am J Geriatr Psychiatry. 2005 Oct;13(10):884-91
16223967
Psychopharmacology (Berl). 2006 Oct;188(3):263-72
16955282
Int J Neuropsychopharmacol. 2010 Feb;13(1):103-8
19835669
Neuropsychobiology. 2006;54(3):152-9
17230032
Pharmacopsychiatry. 2008 Mar;41(2):41-7
18311683
Lancet. 2006 Jun 17;367(9527):1959-62
16782468
Int Clin Psychopharmacol. 2003 Jul;18(4):211-7
12817155
Clin Pharmacokinet. 2007;46(4):281-90
17375980
Drugs. 2005;65(16):2379-404
16266205
Curr Med Res Opin. 2005 Oct;21(10):1659-68
16238906
Curr Med Res Opin. 2007 Feb;23(2):251-8
17288678
Int J Neuropsychopharmacol. 2008 May;11(3):381-8
17697395
Depress Anxiety. 2005;21(1):26-32
15786487
Clin Toxicol (Phila). 2010 Mar;48(3):207-12
20170390
J Clin Psychiatry. 2006 Nov;67(11):1767-75
17196058
Pharmacopsychiatry. 2006 Sep;39(5):180-4
16944409
Aust N Z J Psychiatry. 2004 Jun;38(6):389-407
15209830
Eur J Clin Pharmacol. 1998 May;54(3):237-42
9681666
J Clin Psychiatry. 2001;62 Suppl 8:4-9; discussion 10-1
12108821
Prim Care Companion J Clin Psychiatry. 2001 Dec;3(6):232-235
15014590
J Clin Psychopharmacol. 2009 Aug;29(4):368-71
19593177
Am J Geriatr Psychiatry. 2008 Jan;16(1):14-20
18165459
Expert Opin Pharmacother. 2009 Apr;10(6):927-36
19317630
Pharmacoeconomics. 2008;26(11):969-81
18850765
J Clin Psychiatry. 2005 Dec;66(12):1569-75
16401159
J Clin Psychiatry. 2001;62 Suppl 22:5-9
11599650
J Sex Marital Ther. 2005 May-Jun;31(3):257-62
16020143
Int Clin Psychopharmacol. 2005 May;20(3):139-43
15812263
Neuropsychobiology. 2006;54(4):201-7
17337913
Clin Ther. 2007 Nov;29(11):2319-32
18158074
J Psychiatr Pract. 2008 Sep;14(5):271-80
18832958
Croat Med J. 2010 Feb;51(1):61-73
20162747
J Clin Psychiatry. 2006 May;67(5):736-46
16841623
J Clin Psychopharmacol. 2004 Apr;24(2):209-13
15206668
Indian J Psychiatry. 2004 Oct;46(4):333-41
21206792
Int Clin Psychopharmacol. 2005 May;20(3):131-7
15812262
Nord J Psychiatry. 2007;61(2):100-8
17454724
Lancet. 2009 Feb 28;373(9665):746-58
19185342
AAPS J. 2006 Jan 20;8(1):E14-9
16584121
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006532
19370639
Int Clin Psychopharmacol. 2007 Mar;22(2):107-15
17293711
Am J Psychiatry. 2007 Oct;164(10):1530-8
17898344
Expert Opin Pharmacother. 2009 Apr;10(6):937-45
19364246
Int J Clin Pract. 2005 Dec;59(12):1428-34
16351675